CliffBio
small molecule

SAVAYSA

EDOXABAN TOSYLATE

Loss of exclusivityMarch 2028latest FDA-listed patent expiry
CompanyDaiichi Sankyo →See this company's full patent-cliff portfolio

Drug detail

Brand nameSAVAYSA
Active ingredientEDOXABAN TOSYLATE
StrengthEQ 15MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2015
Marketing statusRX

Listed patents

PatentExpiresType
9149532March 2028product
7365205April 2027substance

Regulatory exclusivity

CodeExpires
M-14October 2026

More from Daiichi Sankyo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.